All articles tagged with #ivonescimab
Summit Therapeutics' stock plummeted nearly 17% after its experimental drug, ivonescimab, failed to improve overall survival in a lung cancer trial, casting doubt on its prospects for FDA approval and future partnerships.
Summit Therapeutics' lung cancer drug ivonescimab showed promising overall survival and progression-free survival results in a Phase 3 trial, but regional differences, especially between Western and Chinese patients, have raised concerns about its competitive potential against Merck's Keytruda, leading to a decline in the company's stock.
Summit Therapeutics' lung cancer drug ivonescimab shows promising results in China but weaker and non-significant benefits in North America and Europe, potentially complicating its approval process in Western markets due to geographic disparities in trial outcomes.
A Phase 3 trial of the drug ivonescimab, which targets PD-1 and VEGF pathways, showed it delayed tumor progression in lung cancer patients but did not significantly extend survival, potentially complicating its path to FDA approval in the US. The results highlight the challenges of demonstrating survival benefits for cancer drugs, despite promising progression-free survival data.
Summit Therapeutics' cancer drug trial results showed mixed outcomes, with the drug performing better than placebo in delaying cancer progression and working equally well in Asian and Western patients, but failing to demonstrate a statistically significant increase in overall survival. Despite the disappointing results, analysts viewed the trial as a positive sign for Chinese biopharma collaborations, though the company's stock dropped significantly due to concerns over FDA approval requirements.
Akeso and Summit Therapeutics' drug ivonescimab showed promising results in delaying progression of certain lung cancers in a global phase 3 trial, with significant improvements in progression-free survival, though overall survival benefits are still being evaluated. The drug demonstrated consistent effects across Asian and Western populations, and the companies plan to seek FDA approval, despite some investor disappointment over the overall survival data.
Summit Therapeutics announced that its lung cancer drug ivonescimab delayed disease progression in a Phase 3 trial, but has not yet shown a survival benefit, raising concerns about its potential FDA approval and blockbuster success, leading to a 30% drop in shares.
Summit Therapeutics' Phase 3 HARMONi-2 study in China showed that their lung cancer therapy ivonescimab significantly improved progression-free survival compared to Merck's Keytruda in patients with advanced non-small cell lung cancer. Despite this positive result, Summit's stock saw a decline after a significant rise the previous day.
Summit Therapeutics Inc. shares soared 272% after a late-stage trial showed their cancer drug ivonescimab significantly outperformed Merck's Keytruda in treating non-small cell lung cancer, leading to a decline in Merck's shares. The trial, conducted in China, demonstrated a meaningful improvement in progression-free survival, with analysts optimistic about the drug's potential in other populations and across multiple solid tumors.